It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

Infections by multidrug resistant organisms (MDROs) are a global health threat with a worrying increasing trend. In fragile ...

Early detection and public health interventions are critical in improving sepsis survival rates and limiting its long-term ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...

LpxC inhibitors are emerging as a promising class of antibiotics targeting Gram-negative bacteria, which are notorious for their resistance to many existing antibiotics. LpxC, an essential enzyme ...

The initial use of combination antimicrobial therapy for gram-negative infections is usually ... risk of superinfection with more-resistant bacteria or fungi. There are no clinical data that ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

Aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ...